methyl 3-(2,4-dioxothiazolidin-3-yl)propanoate | 1033700-43-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: methyl 3-(2,4-dioxothiazolidin-3-yl)propanoate
• 英文别名: Methyl 2,4-dioxo-3-thiazolidinepropanoate；methyl 3-(2,4-dioxo-1,3-thiazolidin-3-yl)propanoate
• CAS: 1033700-43-4
• 化学式: C₇H₉NO₄S
• 分子量: 203.219
• InChiKey: QBTCPDAUUOETBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  89
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 3-(2,4-dioxothiazolidin-3-yl)propanoate 在 氢溴酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 4-[3-(2,4-Dioxo-1,3-thiazolidin-3-yl)propanoylamino]butanoic acid
  参考文献：
  名称：

  WO2019183577A5

  摘要：

  公开号：

  WO2019183577A5
• 作为产物：
  描述：

  3-溴丙酸甲酯 、 1,3-thiazolidine-2,4-dione potassium salt 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以2.8 g的产率得到methyl 3-(2,4-dioxothiazolidin-3-yl)propanoate
  参考文献：
  名称：

  WO2019183577A5

  摘要：

  公开号：

  WO2019183577A5

文献信息

• Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting β-catenin and Ras degradation
  作者：Seonghwi Choi、Hyuntae Kim、Won-Ji Ryu、Kang-Yell Choi、Taegun Kim、Doona Song、Gyoonhee Han

  DOI：10.1016/j.bioorg.2022.106234

  日期：2023.1

  optimization and identified 3-(2-hydroxyethyl)-5-((6-(4-nitrophenyl)pyridin-2-yl)methylene)thiazolidine-2,4-dione (13d) as the most potent compound. 13d displayed antitumor effects in a colorectal cancer model with enhanced inhibition activity on Ras. The results of this study suggest that the further development of 13d could contribute to the development of Ras inhibitors with novel mechanisms of action.

  Ras 蛋白一直被认为是抗癌治疗的一个迷人靶点，因为它的功能异常与癌症密切相关。然而，由于无法通过控制 Ras 激活机制来调节其故障，Ras 一直被认为是不可药用的。最近，针对 G12C 突变的 Lumakras 获得批准，Ras 在抗癌治疗中的治疗兴趣重新焕发活力。在这里，我们展示了一系列化合物，这些化合物通过利用 Wnt/β-catenin 通路与 Ras 之间关系的独特作用机制来抑制 Ras。KYA1797K (1)结合 axin 以稳定导致 Ras 磷酸化和随后降解的 β-catenin 破坏复合物，类似于典型的 β-catenin 调节。基于1的化学结构, 我们进行了结构优化并确定 3-(2-hydroxyethyl)-5-((6-(4-nitrophenyl)pyridin-2-yl)methylene)thiazolidine-2,4-dione ( 13d ) 为最有效的化合物
• Modulators of G-protein coupled receptors
  申请人：Carmot Therapeutics, Inc.

  公开号：US11535660B1

  公开（公告）日：2022-12-27

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor (“GLP?1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple)-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

  本公开的化学实体（如化合物或该化合物的药学上可接受的盐和/或水合物和/或原药）可调节（如激动或部分激动或拮抗）胰高血糖素样肽1受体（"GLP?1R"）和/或胃抑制多肽受体（"GIPR"）。这些化学实体是有用的，例如，用于治疗患有疾病、失调或病症的受试者（例如人类），在这种情况下，调节（例如，激动、部分激动或拮抗）GLP?1R 和/或 GIPR 的活性有利于治疗或预防潜在的病理和/或症状和/或疾病、失调或病症的进展。在一些实施方案中，调节的结果是增强（如增加）现有水平（如正常或低于正常水平）的GLP?1R和/或GIPR活性（如信号传导）。在某些实施方案中，本文所述的化学实体可进一步调节（如减弱、解除耦合）--相对于原生配体的信号转导。本公开还包括组合物以及使用和制造所述化学实体的其他方法。
• Structural exploration, synthesis and pharmacological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives as iNOS inhibitors against inflammatory diseases
  作者：Liang Ma、Heying Pei、Lei Lei、Linhong He、Jinying Chen、Xiaolin Liang、Aihua Peng、Haoyu Ye、Mingli Xiang、Lijuan Chen

  DOI：10.1016/j.ejmech.2014.12.036

  日期：2015.3

  In our previous work, 3I inhibited the LPS-induced iNOS activity and NO production in RAW 264.7 cells and improved joint inflammation and cartilage destruction in inflammatory model. In this study, we synthesized 59 derivatives and bioisosteres on the basis of 3I by Knoevenagel condensation and biologically evaluated for the study of structure-activity relationship (SAR). We found that 7-44 suppressed the iNOS activity (IC50 25.2 mu M) and LPS-induced NO production (IC50 45.6 mu M) in RAW 264.7 cells. As for the SAR study, the dimethoxylphenyl group of 7-44 was potential for a further modification. At a dose of 10 mg/kg, oral administration of 7-44 possessed protective properties in both carrageenan-induced paw edema of male ICR mice and adjuvant-induced arthritis of Lewis female rats. Although the activity of 7-44 was slightly inferior, the PK profiles of 7-44 were superior to those of 3I. (C) 2014 Elsevier Masson SAS. All rights reserved.
• Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase
  作者：Yuli Xie、Yidong Liu、Gangli Gong、Alison Rinderspacher、Shi-Xian Deng、Deborah H. Smith、Udo Toebben、Effie Tzilianos、Lars Branden、Dušica Vidović、Caty Chung、Stephan Schürer、Lutz Tautz、Donald W. Landry

  DOI：10.1016/j.bmcl.2008.03.079

  日期：2008.5

  We report here a class of thiazolidine-2,4-diones and 2-thioxothiazolidin-4-ones as potent inhibitors of the lymphoid specific tyrosine phosphatase (Lyp) identified from high throughput screens. Chemical modi. cation by incorporating the known phosphotyrosine (pTyr) mimics led to the discovery of a salicylate-based inhibitor with submicromolar potency. (c) 2008 Elsevier Ltd. All rights reserved.
• WO2019183577A5
  申请人：——

  公开号：WO2019183577A5

  公开（公告）日：2024-05-13